BLAINTRAVENOUSINJECTABLEPriority Review
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
NIKTIMVO (axatilimab-csfr) by Incyte is colony stimulating factor receptor type 1 (csf-1r) inhibitors [moa]. Approved for colony stimulating factor-1 receptor blocker [epc]. First approved in 2024.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NIKTIMVO (axatilimab-csfr) is a monoclonal antibody that blocks Colony Stimulating Factor-1 Receptor (CSF-1R), a key driver of macrophage proliferation and inflammatory signaling. It is administered intravenously and designed to treat conditions driven by pathological macrophage accumulation and activation. The drug represents a novel immunomodulatory approach targeting innate immune pathology.
Growth
Recent FDA approval (August 2024) positions NIKTIMVO in early growth phase with emerging team opportunities and modest competitive pressure (30% intensity).
Mechanism of Action
Colony Stimulating Factor Receptor Type 1 (CSF-1R) Inhibitors
Pharmacologic Class:
Colony Stimulating Factor-1 Receptor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on NIKTIMVO at Incyte? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.